Most fat-loss peptides come with a qualifier: promising animal data, limited human trials, use at your own discretion. Tesamorelin doesn’t need that disclaimer. It’s one of the only peptides in this space with FDA approval — specifically indicated for the reduction of excess visceral adipose tissue in HIV-associated lipodystrophy.
That regulatory history means the human data is real, the dosing is established, and the mechanism is understood at a clinical level. For athletes and biohackers targeting visceral fat — the metabolically active, hormonally disruptive fat stored deep in the abdominal cavity — tesamorelin is one of the most evidence-backed tools available. Here’s what the research shows.
What Tesamorelin Is
Tesamorelin (brand name Egrifta) is a synthetic analogue of growth hormone-releasing hormone (GHRH). It’s a 44-amino acid peptide identical to endogenous GHRH, with a trans-3-hexenoic acid group added to the N-terminal end — a modification that increases stability and extends plasma half-life compared to native GHRH.
The mechanism is straightforward: tesamorelin binds GHRH receptors in the pituitary, stimulating pulsatile growth hormone release. That GH pulse drives IGF-1 production, which in turn activates lipolysis — particularly in visceral adipose tissue, which is more sensitive to GH-mediated fat mobilization than subcutaneous fat depots.
The key distinction from GH injections: tesamorelin works through the natural pituitary axis, preserving pulsatile release and the feedback mechanisms that regulate GH output. You get the fat-loss signal without the flat, supraphysiological GH profile that comes with direct GH administration.
The Clinical Evidence
Tesamorelin’s clinical trial program is one of the most rigorous in the peptide space — required for FDA approval and conducted across multiple Phase III trials with several hundred patients.
The pivotal trials (LIPO-010 and LIPO-011) produced the following results in HIV-positive patients with excess visceral adipose tissue:
- 15.2% mean reduction in visceral adipose tissue (measured by CT scan) at 26 weeks versus placebo
- Statistically significant improvement in trunk-to-limb fat ratio
- Increased IGF-1 levels consistent with GH stimulation
- Improved triglyceride and cholesterol profiles in dyslipidemic patients
- No significant effect on glucose tolerance at standard doses in most patients
A 52-week extension of the trial confirmed that visceral fat reduction was maintained with continued treatment, and that discontinuation resulted in gradual return of visceral fat — confirming the effect was compound-dependent rather than a permanent metabolic reset.
For context: a 15% reduction in visceral fat is a clinically meaningful change. Visceral fat is not inert storage — it secretes inflammatory cytokines, disrupts insulin signaling, and correlates strongly with cardiovascular risk, hormonal dysfunction, and metabolic syndrome. Reducing it has systemic effects that go well beyond aesthetics.
Why Visceral Fat Is the Target
Not all fat responds equally to GH stimulation. Visceral adipose tissue — the fat surrounding the abdominal organs — has higher density of GH receptors and is more metabolically active than subcutaneous fat. When GH levels rise, visceral fat is preferentially mobilized first.
This is why tesamorelin produces results in the abdominal region that are visible and measurable even when total body weight change is modest. Athletes with low overall body fat but stubborn visceral accumulation — common in athletes who have cycled through high-calorie bulking phases, or those experiencing age-related GH decline — find tesamorelin particularly effective for exactly this depot.
Subcutaneous fat (the fat you can pinch) responds less acutely to GH-mediated lipolysis. For targeting that depot, direct lipolysis compounds like AOD-9604 are more appropriate. Tesamorelin and AOD-9604 target different fat compartments through different mechanisms — and they can be stacked.
Tesamorelin vs. CJC-1295 for Body Composition
Both are GHRH analogues that stimulate pulsatile GH release. The differences:
- Half-life: Tesamorelin has a longer plasma half-life than CJC-1295 without DAC, but shorter than CJC-1295 with DAC. Dosing is once daily.
- Visceral fat specificity: Tesamorelin’s clinical evidence is specifically for visceral fat reduction. CJC-1295’s body composition effects are broader — supporting muscle protein synthesis and general recomposition.
- Clinical validation: Tesamorelin has FDA-approval-level evidence. CJC-1295 has animal data and observational reports from the athletic community.
- IGF-1 elevation: Both elevate IGF-1. Athletes sensitive to IGF-1 effects (joint fluid retention, carpal tunnel symptoms) should monitor accordingly.
For athletes whose primary goal is visceral fat reduction with established clinical backing, tesamorelin is the more targeted choice. For athletes running a GH secretagogue for broader recomposition, sleep quality, and muscle support, CJC-1295 with ipamorelin remains the standard.
Protocol Design
Dose: 1–2 mg per day. The FDA-approved clinical dose is 2 mg/day. Many athletes start at 1 mg and assess response before escalating.
Timing: Before sleep or in the fasted state. GH is most active during slow-wave sleep — timing the dose to align with natural GH pulsatility amplifies the lipolytic window. Fasted morning injection is the alternative for those who prefer daytime dosing.
Cycle length: 12–26 weeks. The clinical trials used 26-week cycles. Most athletes run 12–16 weeks and assess visceral fat change through waist circumference, DEXA, or subjective assessment.
Post-cycle: Visceral fat returns gradually after discontinuation, as confirmed by the extension trials. Tesamorelin is not a permanent intervention — it requires ongoing use to maintain results, or dietary and training changes that independently support visceral fat reduction.
Stack Considerations
- Tesamorelin + AOD-9604: Different mechanisms (GHRH stimulation vs. direct lipolysis), different fat compartments (visceral vs. subcutaneous). Complementary stack for full-body recomposition.
- Tesamorelin + Semaglutide: Semaglutide reduces caloric intake through GLP-1 receptor activation; tesamorelin mobilizes visceral fat through GH stimulation. No known mechanism conflict. Powerful combination for metabolic athletes.
- Tesamorelin + Ipamorelin: Both stimulate GH through different receptor pathways. Tesamorelin acts on GHRH receptors; ipamorelin on ghrelin receptors. Combined effect is additive GH stimulation — used by advanced athletes who want maximum GH output with visceral fat as the primary target.
Purity and Sourcing
Tesamorelin is a 44-amino acid peptide — one of the longer chains in the performance peptide space. Longer chains mean more opportunity for synthesis errors. At ≥98% purity with independent COA documentation, you know the active fraction is correct and the clinical dosing reference applies.
Every Genotech batch is independently tested before shipping. The Certificate of Analysis confirms peptide identity, purity percentage, and batch traceability — the same documentation standard required in clinical-grade production.
Bottom Line
Tesamorelin is the only GHRH analogue with FDA-approval-level clinical evidence for visceral fat reduction. The mechanism is clear, the human data is real, and the dosing is established. For athletes targeting the abdominal fat depot that diet and exercise alone consistently fail to address — particularly visceral fat accumulated through bulking cycles or age-related GH decline — tesamorelin is the most evidence-backed option in the peptide toolkit.
Start at 1 mg. Assess over 12 weeks. Build from evidence.
